IL-3 inhibits TNF-α-induced bone resorption and prevents inflammatory arthritis

Journal of Immunology

Volumn 182, Issue 1, 2009, Pages 361-370

  Yogesha, S D ^a   Khapli, Shruti M ^a   Srivastava, Rupesh K ^a   Mangashetti, Latha S ^a   Pote, Satish T ^a   Mishra, Gyan C ^a   Wani, Mohan R ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN ANTIBODY; COLLAGEN TYPE 2; INTERLEUKIN 1ALPHA; INTERLEUKIN 3; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR ALPHA; VITRONECTIN RECEPTOR; AUTACOID; DNA BINDING PROTEIN; PROTEIN C FOS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BINDING AFFINITY; CARTILAGE; CONTROLLED STUDY; DNA BINDING; GENE TRANSLOCATION; HISTOPATHOLOGY; JOINT; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; ONCOGENE C FOS; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ACTIVE TRANSPORT; ANIMAL; ARTICULAR CARTILAGE; BAGG ALBINO MOUSE; CELL CULTURE; CELL NUCLEUS; DRUG ANTAGONISM; GENETICS; IMMUNOLOGY; METABOLISM; ORGAN CULTURE TECHNIQUE; OSTEOCHONDRITIS; PATHOLOGY; PHYSIOLOGY; PROTEIN BINDING;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, EXPERIMENTAL; BONE RESORPTION; CARTILAGE, ARTICULAR; CELL NUCLEUS; CELLS, CULTURED; COLLAGEN TYPE II; DNA-BINDING PROTEINS; INFLAMMATION MEDIATORS; INTERLEUKIN-3; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; ORGAN CULTURE TECHNIQUES; OSTEOCHONDRITIS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-FOS; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 59849109523     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.182.1.361     Document Type: Article

References (56)

1. + dendritic cells and tartrate-resistant acid phosphatase-positive osteoclast-like multinucleated giant cells from human monocytes. Blood 88: 4029-4039.
2. Assuma, R., T. Oates, D. Cochran, S. Amar, and D. T. Graves. 1998. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J. Immunol. 160: 403-409.
3. Redlich, K., S. Hayer, R. Ricci, J. P. David, M. Tohidast-Akrad, G. Kollias, G. Steiner, J. S. Smolen, E. F. Wagner, and G. Schett. 2002. Osteoclasts are essential for TNF-α-mediated joint destruction. J. Clin. Invest. 110: 1419-1427.
4. Rivollier, A., M. Mazzorana, J. Tebib, M. Piperno, T. Aitsiselmi, C. Robourdin-Combe, P. Jurdic, and C. Servet-Delprat. 2004. Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 104: 4029-4037.
5. Lacey, D. L., E. Timms, H. L. Tan, M. J. Kelley, C. R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
6. Yasuda, H., N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S-I. Mochizuki, A. Tomoyasu, K. Yano, M. Goto, A. Murakami, et al. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor and identical to TRANCE-RANKL. Proc. Natl. Acad. Sci. USA 95: 3597-3602.
7. Azuma, Y., K. Kaji, R. Katogi, S. Takeshita, and A. Kudo. 2000. Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 275: 4858-4864.
8. Kobayashi, K., N. Takahashi, E. Jimi, N. Udagawa, M. Takami, S. Kotake, N. Nakagawa, M. Kinosaki, K. Yamaguchi, N. Shima, et al. 2000. Tumor necrosis factor α stimulates osteoclastic differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191: 275-286.
9. Lam, J., S. Takeshita, J. E. Barker, O. Kanagawa, F. P. Ross, and S. L. Teitelbaum. 2000. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106: 1481-1488.
10. Fuller, K., C. Murphy, B. Kirstein, S. W. Fox, and T. J. Chambers. 2002. TNF-α potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 143: 1108-1118.
11. Yogesha, S. D., S. M. Khapli, and M. R. Wani. 2005. Interleukin-3 and granulocyte-macrophage colony-stimulating factor inhibits tumor necrosis factor (TNF)-α-induced osteoclast differentiation by down-regulation of expression of TNF receptors 1 and 2. J. Biol. Chem. 280: 11759-11769.
12. Zhang, Y. H., A. Heulsmann, M. M. Tondravi, A. Mukherjee, and Y. Abu-Amer. 2001. Tumor necrosis factor-α (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J. Biol. Chem. 276: 563-568.
13. Kitazawa, R., R. B. Kimble, J. L. Vannice, V. T. Kung, and R. Pacifici. 1994. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J. Clin. Invest. 94: 2397-2406.
14. Papadaki, H. A., H. D. Kritikos, C. Gemetzi, H. Koutala, J. C. Marsh, D. T. Boumpas, and G. D. Eliopoulos. 2002. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor α-mediated effect. Blood 99: 1610-1619.
15. Kwan, T. S., M. Padrines, S. Theoleyre, D. Heymann, and Y. Fortun. 2004. IL-6, RANKL, TNF-α/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 15: 49-60.
16. Han, S. Y., N. K. Lee, K. H. Kim, I. W. Jang, M. Yim, J. H. Kim, W. J. Lee, and S. Y. Lee. 2005. Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKL-induced osteoclastogenesis. Blood 106: 1240-1245.
17. Fox, S. W., and A. C. Lovibond. 2005. Current insights into the role of transforming growth factor-β in bone resorption. Mol. Cell Endocrinol. 243: 19-26.
18. Schrader J. W. 2003. Interleukin-3. In The Cytokine Handbook, 2nd Ed. A. W. Thomson, and M. T. Lotze, eds. Academic, London, pp. 201-225.
19. + hematopoietic progenitor cells. Blood 87: 2376-2385.
20. Bryder, D., and S. E. Jacobsen. 2000. Interleukin-3 supports expansion of longterm multilineage repopulating activity after multiple stem cell divisions in vitro. Blood 96: 1748-1755.
21. Shinar, D. M., S. Masahiko, and G. A. Rodan. 1990. The effect of hemopoietic growth factors on the generation of osteoclast-like cells in mouse bone marrow cultures. Endocrinology 126: 1728-1735.
22. Barton, B. E., and R. Mayer. 1989. IL-3 induces differentiation of bone marrow precursor cells to osteoclast-like cells. J. Immunol. 143: 3211-3216.
23. Fujikawa, Y., A. Sabokbar, S. D. Neale, I. Itonaga, T. Torisu, and N. A. Athanasou. 2001. The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1, -3, -6, and -11, tumor necrosis factor-α, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells. Bone 28: 261-267.
24. Lee, J. W., H. Y. Chung, L. A. Ehrlich, D. F. Jelinek, N. S. Callander, G. D. Roodman, and S. J. Choi. 2003. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 103: 2308-2315.
25. Miyamoto, T., O. Ohneda, F. Arai, K. Iwamoto, S. Okada, K. Takagi, D. M. Anderson, and T. Suda. 2001. Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 98: 2544-2554.
26. Khapli, S. M., L. S. Mangashetti, S. D. Yogesha, and M. R. Wani. 2003. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-κB ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. J. Immunol. 171: 142-151.
27. Lean, J. M., K. Fuller, and T. J. Chambers. 2001. FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. Blood 98: 2707-2713.
28. 2+ signaling. J. Immunol. 175: 917-925.
29. Fuller, K., B. Kirstein, and T. J. Chambers. 2007. Regulation and enzymatic basis of bone resorption by human osteoclasts. Clin. Sci. 112: 567-575.
30. Terato, K., D. S. Harper, M. M. Griffiths, D. L. Hasty, X. J. Ye, M. A. Cremer, and J. M. Seyer. 1995. Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity 22: 137-147.
31. Yumoto, K., M. Ishijima, S. R. Rittling, K. Tsuji, Y. Tsuchiya, S. Kon, A. Nifuji, T. Uede, D. T. Denhardt, and M. Noda. 2002. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc. Natl. Acad. Sci. USA 99: 4556-4561.
32. Romas, E., N. A. Sims, D. K. Hards, M. Lindsay, J. M. Quinn, P. J. Ryan, C. R. Dunstan, T. J. Martin, and M. T. Gillespie. 2002. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am. J. Pathol. 161: 1419-1427.
33. Jimi, E., K. Aoki, H. Saito, F. D'Acquisto, M. J. May, I. Nakamura, T. Sudo, T. Kojima, F. Okamoto, H. Fukushima, et al. 2004. Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat. Med. 10: 617-624.
34. Miyamoto, T., F. Arai, O. Ohneda, K. Takaqi, D. M. Anderson, and T. Suda. 2000. An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor κB ligand. Blood 96: 4335-4343.
35. 3 integrin collaborate during osteoclast differentiation. J. Clin. Invest. 111: 749-758.
36. 3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol. Rev. 208: 88-105.
37. Quinn, J. M., and M. T. Gillespie. 2005. Modulation of osteoclast formation. Biochem. Biophys. Res. Commun. 328: 739-745.
38. Miyazaki, T., H. Katagiri, Y. Kanegae, H. Takayanagi, Y. Sawada, A. Yamamoto, M. P. Pando, T. Asano, I. M. Verma, H. Oda, et al. 2000. Reciprocal role of ERK and NF-κB pathways in survival and activation of osteoclasts. J. Cell Biol. 148: 333-342.
39. Xing, L., L. Carlson, B. Story, Z. Tai, P. Keng, U. Siebenlist, and B. F. Boyce. 2003. Expression of either NF-κB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. J. Bone Miner. Res. 18: 260-269.
40. Iotsova, V., J. Caamano, J. Loy, Y. Yang, A. Lewin, and R. Bravo. 1997. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat. Med. 3: 1285-1289.
41. Shiozawa, S., K. Shimizu, K. Tanaka, and K. Hino. 1997. Studies on the contribution of c-fos/AP-1 to arthritic joint destruction. J. Clin. Invest. 99: 1210-1216.
42. Wang, Z. Q., C. Ovitt, A. E. Grigoriadis, U. Mohle-Steinlein, U. Ruther, and E. F. Wagner. 1992. Bone and haematopoietic defects in mice lacking c-Fos. Nature 360: 741-745.
43. Wagner, E. F., and R. Eferl. 2005. Fos/AP-1 proteins in bone and the immune system. Immunol. Rev. 208: 126-140.
44. Wei, S., H. Kitaura, P. Zhou, F. P. Ross, and S. L. Teitelbaum. 2005. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 115: 282-290.
45. Zwerina, J., S. Hayer, M. Tohidast-Akrad, H. Bergmeister, K. Redlich, U. Feige, C. Dunstan, G. Kollias, G. Steiner, J. Smolen, and G. Schett. 2004. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum. 50: 277-290.
46. Lader, C. S., and A. M. Flanagan. 1998. Prostaglandin E2, interleukin 1α, and tumor necrosis factor-αincrease human osteoclast formation and bone resorption in vitro. Endocrinology 139: 3157-3164.
47. Weitzmann, M. N., S. Cenci, L. Rifas, C. Brown, and R. Pacifici. 2000. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood 96: 1873-1878.
48. 3 integrins are osteosclerotic because of dysfunctional osteoclasts. J. Clin. Invest. 105: 433-440.
49. Wilder, R. L. 2002. Integrin αV β3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann. Rheum. Dis. 61(Suppl. 2): ii96 -ii99.
50. Jimi, E., and S. Ghosh. 2005. Role of nuclear factor-κB in the immune system and bone. Immunol. Rev. 208: 80-87.
51. Grigoriadis, A. E., Z. Q. Wang, M. G. Cecchini, W. Hofstetter, R. Felix, H. A. Fleisch, and E. F. Wagner. 1994. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266: 443-448.
52. Ponchel, F., A. W. Morgan, S. J. Bingham, M. Quinn, M. Buch, R. J. Verburg, J. Henwood, S. H. Douglas, A. Masurel, P. Conaghan, et al. 2002. Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood 100: 4550-4556.
53. Firestein, G. S. 2003. Evolving concepts of rheumatoid arthritis. Nature 423: 356-361.
54. 2 receptors in the pathogenesis of rheumatoid arthritis. J. Clin. Invest. 110: 651-658.
55. Lee, J. C., M. J. Dimartino, B. J. Votta, and N. Hanna. 1987. Effect of auranofin treatment on aberrant splenic interleukin production in adjuvant arthritic rats. J. Immunol. 139: 3268-3274.
56. Firestein, G. S., W. D. Xu, K. Townsend, D. Broide, J. Alvaro-Gracia, A. Glasebrook, and N. J. Zvaifler. 1988. Cytokines in chronic inflammatory arthritis: I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis. J. Exp. Med. 168: 1573-1586.